Effects of a medication assistance program with medication therapy management on the health of renal transplant recipients

American Journal of Health-System Pharmacy

Volumn 64, Issue 14, 2007, Pages 1506-1512

  Chisholm, Marie A ^a   Spivey, Christina A ^a   Mulloy, Laura L ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antidiabetic agents; Antilipemic agents; Blood levels; Charity; Clinical pharmacy; Cyclosporine; Diabetes mellitus; Drug distribution; Drug use; Graft rejection; Hyperlipidemia; Hypertension; Hypotensive agents; Immunosuppressive agents; Outcomes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; DEMOGRAPHY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE ACCESS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RECIPIENT; TREATMENT OUTCOME;

EID: 34447553667     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060634     Document Type: Article

References (50)

1. Strum MW, Hopkins R, West DS et al. Effects of a medication assistance program on health outcomes in patients with type 2 diabetes mellitus. Am J Health-Syst Pharm. 2005; 62:1048-52.
2. Hadley J, Holahan J. The cost of care for the uninsured: what do we spend, who pays, and what would full coverage add to medical spending? www.kff.org/uninsured/7084.cfm (accessed 2007 Mar 29).
3. Schur CL, Doty MM, Berk ML. Lack of prescription coverage among the under 65: a symptom of underinsurance. Issue Brief. 2004; 716:1-8.
4. The Henry J. Kaiser Family Foundation. Prescription drug trends. www.kff.org/rxdrugs/3057 (accessed 2007 Mar 29).
5. Cunningham PJ. Affording prescription drugs: not just a problem for the elderly. www.hschange.org/CONTENT/430 (accessed 2007 Mar 29).
6. Taylor H, Leitman R, eds. Out-of-pocket costs are a substantial barrier to prescription drug compliance. www.harrisinteractive.com/news/newsletters/ healthnews/HI_HealthCareNews2001Vol1_iss32.pdf (accessed 2006 Jul 11).
7. Butler JA, Roderick P, Mullee M et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004; 77:769-76.
8. Frazier PA, Davis-Ali SH, Dahl KE. Correlates of noncompliance among renal transplant recipients. Clin Transplant. 1994; 8:550-7.
9. Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation. 1998; 66:1718-26.
10. Chisholm MA, Mulloy LL, Jagadeesan M et al. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant. 2001; 15:330-6.
11. Ghods AJ, Nasrollahzadeh D. Noncompliance with immunosuppressive medications after renal transplantation. Exp Clin Transplant. 2003; 1:39-47.
12. Didlake R, Deyfus K, Kerman R et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc. 1988; 20:63-9.
13. Raiz L, Kilty K, Henry M et al. Medication compliance following renal transplantation. Transplantation. 1999; 68:51-5.
14. Forum of End Stage Renal Disease Networks. Questions patients might ask about kidney transplant. www.esrdnetworks.org/networks/net5/Transplant/ktqa/pts. pdf (accessed 2006 Jul 21).
15. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. Am J Health-Syst Pharm. 2005; 62:1775-81.
16. Matas A, Humar A, Gillingham K et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int. 2002; 62:704-14.
17. Gaston RS, Hudson SL, War M et al. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc. 1999; 31:21S-3S.
18. Rovelli M, Palmeri D, Vossler E et al. Noncompliance in renal transplant recipients: evaluation of socioeconomic groups. Transplant Proc. 1989; 21:3979-81.
19. Rovelli M, Palmeri D, Vossler E et al. Noncompliance in organ transplant recipients. Transplant Proc. 1989; 21:833-4.
20. Chisholm MA, Tackett KL, Kendrick BD et al. Assistance programs available for medications commonly used in transplant patients. Clin Transplant. 2000; 14:269-81.
21. Sarrafizadeh M, Waite NM, Hobson EH et al. Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic. Am J Health-Syst Pharm. 2004; 61:1816-20.
22. Chauncey D, Mullins CD, Tran BV et al. Medication access through patient assistance programs. Am J Health-Syst Pharm. 2006; 63:1254-9.
23. Paris W, Dunham S, Sebastian A et al. Medication nonadherence and its relation to financial restriction. J Transpl Coord. 1999; 9:149-52.
24. Harmon GN, Lefante J, Roy W et al. Outpatient medication assistance program in a rural setting. Am J Health-Syst Pharm. 2004; 61:603-7.
25. Schoen M, DiDomenico R, Connor S et al. Impact of the cost of prescription drugs on clinical outcomes in indigent patients with heart disease. Pharmacotherapy. 2001; 21:1455-63.
26. Spiker E, Giannamore M, Nahata M. Medication use patterns and health outcomes among patients using a subsidized drug program. J Am Pharm Assoc. 2005; 45:714-9.
27. Racusen L, Solez K, Colvin R et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55:713-23.
28. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant. 2003; 3:708-14.
29. Lacy C, Armstrong L, Goldman M et al. Drug information handbook - pocket. Hudson, OH: Lexi-Comp Inc.; 2003.
30. Ware J Jr. SF-36 Health Survey update. www.sf-36.org/tools/sf36.shtml (accessed 2006 Jun 26).
31. Ware J, Kosinski M, Keller S. SF-36 physical and mental health summary scales: a user's manual. Boston: Health Institute; 1994.
32. Akioka K, Takahara S, Ichikawa S et al. Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan. World J Surg. 2005; 29:249-56.
33. Fazelzadeh A, Mehdizadeh A, Ostovan M et al. Predictors of cardiovascular events and associated mortality of kidney transplant recipients. Transplant Proc. 2006; 38:509-11.
34. Kasiske B, Anjum S, Shah R et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004; 43:1071-81.
35. Wissing K, Abramowicz D, Broeders N et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation. 2000; 70:464-72.
36. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant. 2002; 17(suppl 4):25-6.
37. Tutone V, Mark P, Stewart G et al. Hypertension, antihypertensive agents and outcome following renal transplantation. Clin Transplant. 2005; 19:181-92.
38. Chuang P, Gibney E, Chan L et al. Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. Transplant Proc. 2004; 36:1387-91.
39. Revanur V, Jardine A, Kignsmore D et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001; 15:89-94.
40. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-421.
41. Cosio F, Pesavento T, Pelletier R et al. Patient survival after renal transplantation. III. The effects of statins. Am J Kidney Dis. 2002; 40:638-43.
42. Jardine A, Holdaas H, Fellstrom B et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant. 2004; 4:988-95.
43. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43:S1-290.
44. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289:2560-72. [Erratum, JAMA. 2003; 290:197.]
45. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant. 2005; 5:2725-31.
46. Sezer S, Akgul A, Altinoglu A et al. Post-transplant diabetes mellitus: impact of good blood glucose regulation on renal transplant recipient outcome. Transplant Proc. 2006; 38:533-6.
47. Thomas M, Mathew T, Russ G. Glycaemic control and graft loss following renal transplantation. Nephrol Dial Transplant. 2001; 16:1978-82.
48. Grady KL, Naftel DC, White-Williams C et al. Predictors of quality of life at 5 to 6 years after heart transplantation. J Heart Lung Transplant. 2005; 24:1431-9.
49. Hathaway D, Winsett R, Prendergast M et al. The first report from the patient outcomes registry for transplant effects on life (PORTEL): difference in side-effects and quality of life by organ type, time since transplant, and immunosuppressive regimens. Clin Transplant. 2003; 17:183-94.
50. Ware J, Snow K, Kosinski M et al. SF-36 health survey: manual and interpretation guide. Boston: Health Institute; 1993.